CT-P13: design, development, and place in therapy

Figures & data

Table 1 Clinical studies on CT-P13 efficacy

Study	Design	Number of patients	Disease	Assessment of efficacy
Park et al,^Citation49 (South Korea)	Open-label, retrospective, multicenter	173	95 CD 78 UC	CDAI, Mayo score
Jung et al,^Citation50 (South Korea)	Open-label, retrospective, multicenter	110	59 CD 51 UC	CRP, CDAI, Mayo score
Kang et al,^Citation51 (South Korea)	Open-label, case series, tertiary center	17	8 CD 9 UC	CDAI, Mayo score
Keil et al,^Citation52 (Czech Republic)	Open-label, prospective, multicenter	52	30 CD 22 UC	CDAI, Mayo score CRP
Farkas et al,^Citation53 (Czech Republic, Hungary)	Open-label, prospective, multicenter	63	63 UC	Mucosal healing with Mayo subscore
Gecse et al,^Citation55 (Hungary)	Open-label, prospective, observational, multicenter	210	126 CD 84 UC	Mayo score, CRP, platelet count
Farkas et al,^Citation56 (Hungary)	Open-label, prospective, observational, tertiary center	39	18 CD 21 UC	CDAI, Mayo score
Jahnsen et al,^Citation57 (Norway)	Open-label, prospective, observational, single center	78	46 CD 32 UC	Mayo score, CRP, calprotectin
Schulze et al,^Citation58 (Germany)	Open-label, prospective, multicenter	86 IFX 33 CT-P13	IBD	Serum levels and drug antibodies
Fiorino et al,^Citation60 (Italy)	Open-label, prospective, multicenter, tertiary center	547	313 CD 234 UC	Mayo score Harvey–Bradshaw

Abbreviations: CD, Crohn’s disease; CDAI, Crohn’s Disease Activity Index; UC, ulcerative colitis; CRP, C-reactive protein; IBD, inflammatory bowel disease; IFX, infliximab.

Table 2 Summary of published studies reporting the outcome of patients switched from infliximab to CT-P13

Study/authors	Disease of interest	Number of patients	Evaluation of efficacy	Evaluation of safety after switch
PLANETAS^Citation39	Ankylosing spondylitis	86	Similar efficacy	Comparable safety and immunogenicity
PLANETRA^Citation41	Rheumatoid arthritis	144	Similar efficacy	Comparable safety and immunogenicity
Park et al^Citation49	IBD	40 CD, 16 UC	81% CD, 45.5% UC	Not specified
Jung et al^Citation50	IBD	27 CD, 9 UC	93% CD, 67% UC	Not specified
Kang et al^Citation51	IBD	5 CD, 4 UC	89%	Not specified
Nikiphorou et al^Citation64	Rheumatoid arthritis	39	No statistical difference for symptoms and lab tests	No difference
Fiorino et al^Citation60	IBD	53 CD, 44 UC	79% at 32 weeks	No difference
Sieczkowska et al^Citation62	Paediatric IBD	32 CD, 7 UC	80% CD, 100% UC	No difference

Abbreviations: IBD, inflammatory bowel disease; CD, Crohn’s disease; UC, ulcerative colitis.

ParkSKimYLeeJPost-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in KoreaExpert Rev Gastroenterol Hepatol20159 35 4426395533

 PubMedGoogle Scholar

JungYSParkDIKimYHEfficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter studyJ Gastroenterol Hepatol20153012 1705 171225974251

 PubMed Web of Science ®Google Scholar

KangYMoonHLeeSLimYKangHClinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case seriesDig Dis Sci201560 951 95625326115

 PubMed Web of Science ®Google Scholar

KeilRWasserbauerMZádorováZClinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn’s disease and ulcerative colitisScand J Gastroenterol2016519 1062 106827002981

 PubMed Web of Science ®Google Scholar

FarkasKRutkaMGolovicsPAEfficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitisJ Crohns Colitis20161011 1273 127827106537

 PubMed Web of Science ®Google Scholar

GecseKLovaszBFarkasKEfficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohortJ Crohn’s Colitis2015102 133 14026661272

 PubMedGoogle Scholar

FarkasKRutkaMBalintAEfficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis – experiences from a single centerExpert Opin Biol Ther201515 1257 126226134250

 PubMed Web of Science ®Google Scholar

JahnsenJDetlieTVatnSRicanekPBiosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: a Norwegian observational studyExpert Rev Gastroenterol Hepatol20159 45 5226395534

 PubMedGoogle Scholar

SchulzeKKoppkaNLutterFBrandhorstGSchreiberSHelwigUCT-P13(Inflectra™, Remsima™) monitoring in patients with inflammatory bowel diseaseBiologicals2016445 463 46627435444

 PubMed Web of Science ®Google Scholar

FiorinoGManettiNArmuzziAThe PROSIT-BIO cohort: a prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilarInflamm Bowel Dis201723 233 24328092307

 PubMed Web of Science ®Google Scholar

ParkWYooDHJaworskiJComparable long-term efficacy, as assessed by patient reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS studyArthritis Res Ther201618 2526795209

 PubMed Web of Science ®Google Scholar

YooDHRacewiczABrzezickiJA phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA studyArthritis Res Ther201618 8227038608

 PubMed Web of Science ®Google Scholar

NikiphorouEKautiainenHHannonenPClinical effectiveness of CT-P13 (infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational dataExpert Opin Biol Ther201515 1677 168326549204

 PubMed Web of Science ®Google Scholar

SieczkowskaJJarzębickaDBanaszkiewiczASwitching between infliximab originator and biosimilar in pediatric patients with inflammatory bowel disease: preliminary observationJ Crohn’s Colitis2015102 127 13226721942

 PubMedGoogle Scholar